Introduction
This resource is mainly about changing HIV treatment (ART) because of drug resistance.
This covers about 50 pages online (many of them are short). The PDF booklet is an 8-page summary with QR code links to the online sections.
The information covers:
- When you might need to change ART.
- Why you might need to change ART.
- Which tests are used and what the results mean.
- How to choose your next meds.
- How to make sure the next treatment will work.
It also includes:
- Drug resistance.
- New drugs and other research.
This 17th edition has been revised and updated throughout.
- ART in the UK is now very effective. Only about 1 in 20 people (5%) need to change their first treatment because it does not work.
- Also, less than 1 in 20 people (5%) who are on stable treatment need to change each year due to resistance.
- Even with drug resistance, most people still have new drugs that will work.
- Lenacapavir is a 6-monthly injection that is also available for emergency use. This is only if you have extensive drug resistance. Lenacapavir needs to be used with other active meds.
- Fostemsavir and ibalizumab can be used if you have drug resistance to all other classes.
- Other pipeline drugs are being developed that can overcome resistance to current HIV meds.
This online guide includes detailed information.
A related printed leaflet just includes a summary with links to the website.
The information is based on choices in the UK, Europe and the US.
Information is based on treatment guidelines at this link:
i-base.info/treatment-guidelines
Although choices will be more limited in many other countries, the approach will still be similar.
Changes to this edition
The main changes are:
- Updated information about the latest drugs and about ongoing research.
- New information about the WHO guidelines for people living in low- and middle-income countries.
- Information is included about long-acting injectable ART. This might be an important option if you have difficulty taking daily pills.
Last updated: 1 January 2025.